Mouscron

Researchers are evaluating a new approach to radiotherapy for patients with glioblastoma, a common and aggressive brain tumor. This trial aims to determine if focusing radiation treatment more precisely by reducing the usual safety margin can safely decrease side effects and improve quality of life. Despite current treatments involving surgery, radiotherapy, and chemotherapy, survival remains limited and quality of life is often impaired for these patients. The study compares two radiotherapy approaches one with the standard irradiation volume including a 15mm safety margin around the tumor, and another with a reduced 10mm margin to limit the amount of healthy brain tissue exposed. Both groups receive chemoradiotherapy as part of their treatment. This national multicenter trial will randomize patients to either the standard or reduced radiotherapy volume to assess outcomes. Participants will be followed for up to two years with regular assessments of overall survival, neurocognitive function, treatment-related toxicity, quality of life, disease progression, and recurrence patterns. Evaluations include baseline measurements and follow-ups at one month and one year after radiotherapy. Researchers will also monitor use of anti-edema therapy during the study. The total participation duration and study procedures are designed to monitor safety and the impact of the radiation volume on patient well-being.

Researchers are studying women with a recent history of gestational diabetes GDM who have persistent glucose intolerance early after childbirth. These women are at high risk of developing type 2 diabetes T2DM, with about half progressing within five years. The study aims to evaluate whether the long-acting drug semaglutide can reduce the risk of developing T2DM compared to a placebo in this group. Women will be randomly assigned to receive either semaglutide or a placebo injection once weekly, alongside lifestyle advice. Semaglutide will be gradually increased to a 1mg weekly dose over eight weeks and continued for up to three years. After stopping the study medication, participants will have an oral glucose tolerance test 3 to 6 months later. The study is conducted across several centers and follows participants for a total of about three years. During the study, participants will have regular assessments measuring blood sugar control, body weight, insulin function, heart and metabolic health, and quality of life using questionnaires. Blood tests will monitor glucose, insulin sensitivity, cholesterol, and other biomarkers. Researchers will track the development of T2DM, need for additional diabetes treatments, and weight changes. Health economic factors and patient satisfaction will also be evaluated. The study includes thorough safety and follow-up evaluations lasting beyond the treatment period.